Gilead Sciences Inc
GILD
View Detailed Chart
138.090USD
+0.750+0.55%
Close 03/24, 16:00（ET）Quotes delayed by 15 min
837.59BMarket Cap
20.19P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.55%
5 Days
-4.90%
1 Month
-7.84%
6 Months
+20.71%
Year to Date
+12.51%
1 Year
+28.96%
View Detailed Chart
TradingKey Stock Score of Gilead Sciences Inc
Currency: USD Updated: 2026-03-23Key Insights
Gilead Sciences Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 8 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 157.90.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Gilead Sciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
Gilead Sciences Inc Highlights
StrengthsRisks
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It operates in more than 35 countries worldwide.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 29.44B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 814.79%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 814.79%.
Fairly Valued
The company’s latest PE is 20.08, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.15B shares, decreasing 0.27% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 25.90K shares of this stock.
Analyst Rating
Based on
33
analysts
Buy
Current Rating
157.901
Target Price
+15.08%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Gilead Sciences Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Gilead Sciences Inc Info
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It operates in more than 35 countries worldwide.
Ticker SymbolGILD
CompanyGilead Sciences Inc
CEOO'Day (Daniel P)
Websitehttps://www.gilead.com/
Related Instruments
-0.43%
-0.04%
+1.17%
+1.91%
+0.06%
+1.77%
-0.37%
-0.53%
+0.07%
+1.03%
+1.19%
+2.11%
-0.16%
-1.19%
0.00%
-0.29%
+1.20%
+0.24%
+1.12%Popular Symbols
251.690
+0.200 (+0.08%)
175.270
+2.570 (+1.49%)
70061.180
-824.410 (-1.16%)
300.990
+7.890 (+2.69%)
2147.620
-11.370 (-0.53%)
383.090
+15.130 (+4.11%)
4465.700
+59.010 (+1.34%)
88.063
-0.635 (-0.72%)
1.161
-0.001 (-0.05%)
158.738
+0.309 (+0.19%)
